Compare Abbott Laboratories (ABT) vs Williams Companies Inc (WMB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Williams Companies Inc — how do they compare? Abbott Laboratories trades at $95.59 (market cap $166.94B), while Williams Companies Inc trades at $75.05 (market cap $91.82B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Williams Companies Inc pays the higher dividend (2.8%). Which is the better fit depends on your goals.
| ABT | WMB | |
|---|---|---|
Market Cap | $166.94B | $91.82B |
Sector | Health | Energy |
52-Week High | $136.62 | $79.40 |
52-Week Low | $82.57 | $56.51 |
Enterprise Value | $193.69B | $121.21B |
Dividend Yield | 2.63% | 2.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Williams Companies (WMB) trades at $75.08, up 2.65% on the day, approaching its 52-week high of $80.08. The stock shows strong profitability with a 23.4% net income margin and 21.95% ROE, though valuation ratios like P/E of 31.94 appear elevated. Recent news highlights a potential $5.5 billion acquisition of Momentum Midstream to expand natural gas infrastructure, while technical indicators signal a bearish trend despite neutral oscillators.
WMB presents a mixed outlook: robust cash flow growth and a 79% analyst buy rating support upside to the $86.55 consensus target, but high debt levels and recent earnings misses pose risks. The stock's current price near resistance at $75 suggests near-term consolidation, with long-term growth hinging on successful integration of acquisitions and stable energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
